Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of Genomic Health stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $77.42, for a total transaction of $232,260.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

James J. Vaughn also recently made the following trade(s):

  • On Tuesday, January 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $67.06, for a total transaction of $201,180.00.
  • On Thursday, December 6th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The stock was sold at an average price of $75.30, for a total transaction of $225,900.00.

GHDX stock traded up $1.73 during trading on Monday, hitting $80.42. The company had a trading volume of 258,832 shares, compared to its average volume of 332,858. The company has a market capitalization of $2.87 billion, a P/E ratio of 8,042.00 and a beta of 0.88. Genomic Health, Inc. has a fifty-two week low of $30.04 and a fifty-two week high of $92.18.

GHDX has been the subject of several analyst reports. BidaskClub downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Raymond James initiated coverage on shares of Genomic Health in a report on Tuesday, October 23rd. They set a “market perform” rating for the company. Zacks Investment Research reissued a “hold” rating on shares of Genomic Health in a report on Tuesday, November 13th. Needham & Company LLC initiated coverage on shares of Genomic Health in a report on Wednesday, January 2nd. They set a “strong-buy” rating and a $86.00 price target for the company. Finally, CIBC started coverage on shares of Genomic Health in a report on Wednesday, December 19th. They set a “market perform” rating for the company. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $58.50.

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in Genomic Health by 30.7% in the second quarter. Bank of New York Mellon Corp now owns 122,246 shares of the medical research company’s stock worth $6,161,000 after buying an additional 28,710 shares during the last quarter. Northern Trust Corp increased its position in shares of Genomic Health by 4.7% during the second quarter. Northern Trust Corp now owns 282,021 shares of the medical research company’s stock valued at $14,214,000 after acquiring an additional 12,597 shares during the last quarter. Bank of Montreal Can increased its position in shares of Genomic Health by 12.1% during the third quarter. Bank of Montreal Can now owns 38,854 shares of the medical research company’s stock valued at $2,728,000 after acquiring an additional 4,202 shares during the last quarter. Scout Investments Inc. increased its position in shares of Genomic Health by 2.2% during the third quarter. Scout Investments Inc. now owns 80,397 shares of the medical research company’s stock valued at $5,645,000 after acquiring an additional 1,700 shares during the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in shares of Genomic Health during the third quarter valued at approximately $431,000. 90.09% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/genomic-health-inc-ghdx-insider-sells-232260-00-in-stock/2813602.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.